Serous BMP8A has clinical significance in ultrasonic diagnosis of thyroid cancer and promotes thyroid cancer cell progression.
This study is to discover potential cytokine biomarker for early diagnosis of thyroid cancer. We employed data mining The Cancer Genome Atlas (TCGA) and experimentally elucidated its mechanistic contributions, the differential expression genes (DEGs) between thyroid cancer and health population were analyzed with TCGA online bioinformatic tools. The relative expression of Bone Morphogenetic Protein 8A (BMP8A) was determined by real-time PCR in ultrasonic diagnosed thyroid cancer both in vivo and in vitro. The serous BMP8A content was quantified with ELISA kit. Protein levels of BMP8A, OCLN, ZEB1, EZH2 and β-Actin were analyzed by western blotting. Cell viability was measured by MTT assay and anchorage-independent growth was measured by soft agar colony formation assay. Cell migrative and invasive capacities were interrogated with transwell chambers. We identified aberrant high-expression of BMP8A in thyroid cancer, which associated with unfavorable prognosis and tumor progression. The serous BMP8A was significantly up-regulated in thyroid cancer patients as well. Ectopic over-expression of BMP8A remarkably stimulated cell viability and anchorage-independent growth. Meanwhile, the migrative and invasive capacities were greatly increased in response to BMP8A over-expression. Mechanistically, we characterized positive correlation between BMP8A and TCF7L1, and forced expression of TCF7L1 induced increase of BMP8A in TPC-1 cells. In summary, we identified a novel biomarker for early diagnosis in addition to Ultrasound of thyroid cancer, which was subjected to TCF7L1 regulation.